# Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

> **NCT04878029** · PHASE1 · RECRUITING · sponsor: **Emory University** · enrollment: 32 (estimated)

## Conditions studied

- Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
- Locally Advanced Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Unresectable Urothelial Carcinoma

## Interventions

- **DRUG:** Cabozantinib S-malate
- **DRUG:** Enfortumab Vedotin
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04878029
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-23
- **Primary completion:** 2027-11-13
- **Final completion:** 2028-12-21
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04878029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04878029, "Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04878029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*